Name | Title | Contact Details |
---|---|---|
Linda Dang |
Director, Product Quality Assurance | Profile |
Alicia Goodman |
Senior Vice President Human Resources | Profile |
Galena Biopharma, Inc. is a biopharmaceutical company committed to the development and commercialization of targeted oncology therapeutics that address major unmet medical needs. Galena’s development portfolio is focused primarily on addressing the rapidly growing patient populations of cancer survivors by harnessing the power of the immune system to prevent cancer recurrence. The Company’s pipeline consists of multiple mid- to late-stage clinical assets, including novel cancer immunotherapy programs led by NeuVax™ (nelipepimut-S) and GALE-301. NeuVax is currently in a pivotal, Phase 3 clinical trial with several concurrent Phase 2 trials ongoing both as a single agent and in combination with other therapies. GALE-301 is in a Phase 2a clinical trial in ovarian and endometrial cancers and in a Phase 1b given sequentially with GALE-302.
Discovering new medicines by combining ultra throughput biochemistry and machine learning.
Nashai is a Nashville, TN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
CerFlux Personalized Medicine aims to reduce the pain, reduce the discomfort, and reduce the cost of cancer treatment.
THEON is a patient-focused drug discovery company developing small molecule correctors of RNA pathobiology.